Gunderson Dettmer represented client Alamar Biosciences, a precision proteomics company, in its $80 million Series B financing led by Sherpa Healthcare Partners. The new capital will accelerate the development of Alamar’s proprietary proteomics platform, which will be the most sensitive, highly multiplexed, and high dynamic range solution for life science research, pharmaceutical development, and diagnostics such as liquid biopsy.

In the announcement of the transaction, Founder, Chairman and CEO of Alamar Dr. Yuling Luo said, “We are very pleased to have these top-tier investors supporting our next phase of

development. They bring tremendous amount of expertise in life sciences and diagnostics, which will be extremely valuable to us as we build the company.”

The Gunderson deal team was led by Ivan Gaviria and Nate Gray and included Chase Beckstead.